MYOV News and Press, Myovant Sciences Ltd. From 07/28/21

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q1 2021 Earnings Call Jul 28, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript

Myovant Sciences (NYSE: MYOV) stock is losing ground after the company reported earnings for its fiscal first quarter, the three-month period ended June 30, 2021. Investors upset about net product sales that weren't very impressive led the stock 12.5% lower this morning. The stock r...

Gainers: Bit Digital (BTBT) +51%.Infinity Pharmaceuticals (INFI) +46%.NanoVibronix (NAOV) +40%.Tilray (TLRY) +26%.Flora Growth Corp. (FLGC) +25%.Youdao (DAO) +24%.Grove (GRVI) +22%.Zhangmen Education (ZME) +23%.First High-School Education (FHS) +22%.Canaan (CAN) +21%.Losers: Hoegh LNG Partner...

Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Conference Call July 28, 2021 08:30 A.M. ET Company Participants Ryan Crowe - VP, IR Dave Marek - CEO Lauren Merendino - CCO Frank Karbe - President and CFO Juan Camilo Arjona Ferreira - Chief Medical Officer Conference Call Participants Jason But...

Myovant Sciences shares slide ([[MYOV]] -10.8%) after the company reported first-quarter results that missed Wall Street estimates.Quarterly revenue rose 23% to $41.06M, but missed analysts' average estimate by $20.76M.The company's net loss during the quarter widened to $61.7M, or $0.67...

Myovant Sciences (MYOV): Q1 GAAP EPS of -$0.67 misses by $0.36.Revenue of $41.06M (+23.2% Y/Y) misses by $20.76M.Myovant remains well-capitalized with cash, cash equivalents, marketable securities, and committed funding of $611.1 million as of June 30, 2021, excluding $115.0 million of r...

First fiscal quarter 2021 total revenues of $41.1 million; net product revenue from U.S. sales of ORGOVYX ® of $10.5 million and MYFEMBREE ® of $1.1 million MYFEMBREE approved by the U.S. FDA in May 2021 as the first and only once-daily oral t...

Myovant Sciences (MYOV) announces that the European Commission ((EC)) has approved the marketing authorization application ((MAA)) for Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult wome...

RYEQO is the first and only once-daily long-term treatment for uterine fibroids in Europe Indication has no limitation for duration of use, as supported by safety and efficacy data from the Phase 3 LIBERTY program Gedeon Richter to commercialize RYEQO, starting in t...

BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal...